STRO
SUTRO BIOPHARMA, INC.
NASDAQ · Healthcare · Biotechnology · US
$9.94
+4.52%Oct 21, 2026, 12:00 UTC
SUTRO BIOPHARMA, INC. announced that the first patient had been dosed in its Phase 1 trial of STRO-006 in patients with advanced solid tumors.
Source:Aug 12, 2026, 00:00 UTC
Sutro Biopharma reported Q2 2026 revenue of $9.8 million, down from $63.7 million in Q2 2025, with a net loss of $38.5 million and diluted EPS of -$2.33.
Jul 8, 2026, 00:00 UTC
Aura Biosciences appointed Jeremy Bender as a Class II director effective July 7, 2026.